Global Information
회사소개 | 문의 | 비교리스트

각막염 : 파이프라인 리뷰

Keratitis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 200462
페이지 정보 영문 84 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


각막염 : 파이프라인 리뷰 Keratitis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 84 Pages

각막염이란 각막의 염증입니다. 증상으로는 눈의 충혈, 통증, 시각 저하, 시력 저하, 빛에 대한 과민증 등이 나타납니다. 위험인자로 바이러스 감염, 상처, 기후 조건, 면역력 저하 등을 들 수 있습니다.

각막염 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

각막염 - 개요

각막염 - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 대학·연구기관별 파이프라인 동향
  • 기업에서 개발중인 제품
  • 대학·연구기관에서 개발중인 제품

각막염 - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

각막염 치료제 개발에 참여하고 있는 기업

  • Adamis Pharmaceuticals Corp
  • Dompe Farmaceutici SpA
  • Editas Medicine Inc
  • EyeGate Pharmaceuticals Inc
  • NanoViricides Inc
  • RegeneRx Biopharmaceuticals Inc
  • SIFI SpA
  • The Medicines Company

약제 개요

각막염 - 휴지중인 프로젝트

각막염 - 개발이 중지된 제품

각막염 - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Keratitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Keratitis - Pipeline by Alfasigma SpA, H1 2020
  • Keratitis - Pipeline by AmebaGone Inc, H1 2020
  • Keratitis - Pipeline by Cumulus Pharmaceutical LLC, H1 2020
  • Keratitis - Pipeline by Dobecure SL, H1 2020
  • Keratitis - Pipeline by Editas Medicine Inc, H1 2020
  • Keratitis - Pipeline by Eleusis Ltd, H1 2020
  • Keratitis - Pipeline by EyeGate Pharmaceuticals Inc, H1 2020
  • Keratitis - Pipeline by Fox Chase Chemical Diversity Center Inc, H1 2020
  • Keratitis - Pipeline by iVeena Delivery Systems Inc, H1 2020
  • Keratitis - Pipeline by MimeTech Srl, H1 2020
  • Keratitis - Pipeline by NanoViricides Inc, H1 2020
  • Keratitis - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2020
  • Keratitis - Pipeline by Riptide Bioscience Inc, H1 2020
  • Keratitis - Pipeline by Shulov Innovative Science Ltd, H1 2020
  • Keratitis - Pipeline by SIFI SpA, H1 2020
  • Keratitis - Pipeline by Sinsa Labs Inc, H1 2020
  • Keratitis - Pipeline by TGV-Inhalonix Inc, H1 2020
  • Keratitis - Pipeline by Veloce BioPharma LLC, H1 2020
  • Keratitis - Pipeline by Viraze, H1 2020
  • Keratitis - Dormant Projects, H1 2020
  • Keratitis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Keratitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H1 2020, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 12 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratitis - Overview
    • Keratitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Keratitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Keratitis - Companies Involved in Therapeutics Development
    • Alfasigma SpA
    • AmebaGone Inc
    • Cumulus Pharmaceutical LLC
    • Dobecure SL
    • Editas Medicine Inc
    • Eleusis Ltd
    • EyeGate Pharmaceuticals Inc
    • Fox Chase Chemical Diversity Center Inc
    • iVeena Delivery Systems Inc
    • MimeTech Srl
    • NanoViricides Inc
    • RegeneRx Biopharmaceuticals Inc
    • Riptide Bioscience Inc
    • Shulov Innovative Science Ltd
    • SIFI SpA
    • Sinsa Labs Inc
    • TGV-Inhalonix Inc
    • Veloce BioPharma LLC
    • Viraze
  • Keratitis - Drug Profiles
    • acyclovir sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-2088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologics for Bacterial Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ELE-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ethamsylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Herpetic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imbetasin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IVMED-90 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDE-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KU-55933 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PIM-45 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • polihexanide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-557 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Herpetic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • targocil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udonitrectag - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBP-245 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-9445 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZEP-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZEP-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Keratitis - Dormant Projects
  • Keratitis - Discontinued Products
  • Keratitis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 02, 2020: New provide pandemic response program to clients for TB4 in Corneal Wound Healing and Regeneration
      • Oct 23, 2019: Eleusis presents new research on the anti-inflammatory potential of serotonin 2A receptor agonists at the 2019 International Society for Research on Psychedelics
      • Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis
      • Oct 13, 2017: ODAK Project:Phase III Clinical Trial is ready to start in Italy
      • Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China
      • May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease
      • Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday
      • Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials
      • Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial
      • Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259
      • Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q